the increase in sales in 2020, adjusted for currency effects by up to 7 percent and earnings by up to 5 percent, as the Dax group announced. “We are firmly convinced that to achieve this year as a result of growth,” said CEO Stephan storm on Thursday in Bad Homburg. Last year, the profit currency had been stagnant adjusted. Fresenius 50,70 EUR 2,06 (+4,24%) Xetra
- 1 day
- 6 months
course data
Coronavirus meets Chinese production site: Sales volume of the infusions business is likely to shock get
For against wind but now is the Coronavirus. Fresenius, with the divisions of clinics, liquid medicine, and infusions (Kabi), as well as the dialysis subsidiary FMC is mainly engaged in Europe and the USA. Kabi has production sites in China, because of the new type of lung disease to a standstill, said storm. The division will get the consequences of the Coronavirus to feel the sold volume.
In the people’s Republic of access to hospitals was limited, and supply chains would be disrupted. “It will be a lot of work from stock,” said storm. Also, many of the precursors would be for medicines from China. The longer the Virus-to stop epidemic, the more likely bottlenecks would be.
Also, the dialysis subsidiary Fresenius Medical Care (FMNC) China had declared to the growth of the market. Worldwide there is where the majority of dialysis patients, but only 45 percent of the Chinese had with chronic kidney failure have access to treatment. The treatments in the centers continued in spite of the Coronavirus, however, there are problems to sell equipment for home dialysis. Because of the lung diseases, many Chinese stay home.
business Outlook is retained, but the boss is a back door, keeping open
The business Outlook for the current year, the storm left a back door. Therein, the possible consequences of the Coronavirus were not included. It was too early to quantify this. Currently, Fresenius do not expect any significant negative financial impact.
Fresenius with good 294.000 employees worldwide and has a rough year. So had to pay in the hospital business declining the case, the Trend to outpatient treatment, and stricter rules charged. In the case of liquid medicine, and infusions of the group came in the USA under price pressure. Storm had explained to 2019 to the year of Transition and to fight after two profit warnings in a row with a lot of skepticism on the stock exchange. Now Fresenius shares climbed more than 5 percent.
storm to the 2018er-business figures: “This is not our claim”
last year, group sales rose by 8 percent to EUR 35.5 billion. The profit grew the bottom line by 2 percent to 1.9 billion euros, excluding exchange rate effects, stagnated. “This is not our claim,” said storm.
During the dialysis subsidiary Fresenius Medical Care increased in the fourth quarter, the decline in the results with liquid medicines, infusions and clinical nutrition. The hospital business has stabilized, however. Fresenius is a Germany’s largest hospital operator and had bought his Spanish clinic daughter Quironsalud last several houses in Colombia. Also, the entry into a third European country, in the hospital business is conceivable, stressed storm.
Fresenius was well prepared for the future, he said. “That’s why we look confidently to the front and confirm our ambitious medium-term targets.” The shareholders will receive a dividend of 0.84 euros per share to 0.80 euros in the previous year.
Also interesting: PUSH – bargain find – German stock exchanges at record rates, but these shares are still cheap Invest like a Pro: With the Bernecker exchange-compass, you depend on the Dax! (Partner offer) Now 30 days free of charge test! Take it away! Say goodbye to four thinking errors to become finally rich FOCUS Online, away with it! Say goodbye to four thinking errors to become finally rich
hyo/dpa
